In addition, we identified two novel pathogenic variants and expand the mutational spectrum of the gene OTC, which may contribute to a better understanding of the clinical and genetic characteristics of OTCD patients. This evidence concerns the gene OTC and ornithine carbamoyltransferase deficiency.